TW202334216A - 抗cd47抗體及其使用方法 - Google Patents
抗cd47抗體及其使用方法 Download PDFInfo
- Publication number
- TW202334216A TW202334216A TW111140895A TW111140895A TW202334216A TW 202334216 A TW202334216 A TW 202334216A TW 111140895 A TW111140895 A TW 111140895A TW 111140895 A TW111140895 A TW 111140895A TW 202334216 A TW202334216 A TW 202334216A
- Authority
- TW
- Taiwan
- Prior art keywords
- amino acid
- seq
- acid sequence
- cdr
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/CN2021/126597 | 2021-10-27 | ||
| PCT/CN2021/126597 WO2023070353A1 (en) | 2021-10-27 | 2021-10-27 | Anti-cd47 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202334216A true TW202334216A (zh) | 2023-09-01 |
Family
ID=86160307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111140895A TW202334216A (zh) | 2021-10-27 | 2022-10-27 | 抗cd47抗體及其使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240417463A1 (https=) |
| EP (1) | EP4423138A4 (https=) |
| JP (1) | JP2024542978A (https=) |
| KR (1) | KR20240111823A (https=) |
| CN (1) | CN118434769A (https=) |
| AU (1) | AU2022376756A1 (https=) |
| CA (1) | CA3235611A1 (https=) |
| TW (1) | TW202334216A (https=) |
| WO (2) | WO2023070353A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025010272A1 (en) | 2023-07-03 | 2025-01-09 | Neoimmunetech, Inc. | Heterodimeric fc molecules and uses thereof |
| TW202517683A (zh) * | 2023-07-20 | 2025-05-01 | 美商艾克塞里克斯公司 | 可活化之ror結合劑及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2477648B1 (en) * | 2009-09-15 | 2022-07-20 | The Board of Trustees of the Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| US9517276B2 (en) * | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| EP3668897B1 (en) * | 2017-08-18 | 2024-06-05 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| KR20200091901A (ko) * | 2017-12-01 | 2020-07-31 | 시애틀 지네틱스, 인크. | 암을 치료하기 위한 cd47 항체 및 이의 용도 |
| EP3802599B1 (en) * | 2018-06-03 | 2023-12-20 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| MA53333A (fr) * | 2018-07-31 | 2021-11-03 | Amgen Inc | Formulations pharmaceutiques d'anticorps masqués |
| US20220233709A1 (en) * | 2019-06-05 | 2022-07-28 | Seagen Inc. | Masked Antibody Formulations |
| US20220306727A1 (en) * | 2019-06-05 | 2022-09-29 | Seagen Inc. | Methods of Purifying Masked Antibodies |
| EP4034171A1 (en) * | 2019-09-23 | 2022-08-03 | Cytomx Therapeutics Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
-
2021
- 2021-10-27 WO PCT/CN2021/126597 patent/WO2023070353A1/en not_active Ceased
-
2022
- 2022-10-27 JP JP2024524985A patent/JP2024542978A/ja active Pending
- 2022-10-27 EP EP22886052.4A patent/EP4423138A4/en active Pending
- 2022-10-27 TW TW111140895A patent/TW202334216A/zh unknown
- 2022-10-27 CA CA3235611A patent/CA3235611A1/en active Pending
- 2022-10-27 WO PCT/CN2022/127875 patent/WO2023072177A1/en not_active Ceased
- 2022-10-27 KR KR1020247017377A patent/KR20240111823A/ko active Pending
- 2022-10-27 AU AU2022376756A patent/AU2022376756A1/en active Pending
- 2022-10-27 CN CN202280084763.1A patent/CN118434769A/zh active Pending
- 2022-10-27 US US18/705,386 patent/US20240417463A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4423138A4 (en) | 2026-03-04 |
| KR20240111823A (ko) | 2024-07-17 |
| WO2023072177A1 (en) | 2023-05-04 |
| JP2024542978A (ja) | 2024-11-19 |
| CN118434769A (zh) | 2024-08-02 |
| WO2023070353A1 (en) | 2023-05-04 |
| US20240417463A1 (en) | 2024-12-19 |
| EP4423138A1 (en) | 2024-09-04 |
| CA3235611A1 (en) | 2023-05-04 |
| AU2022376756A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7678841B2 (ja) | 抗ｃｔｌａ４抗体ならびにその作製及び使用方法 | |
| US12173064B2 (en) | Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses | |
| US11952681B2 (en) | Masked activatable CD137 antibodies | |
| US10808030B2 (en) | Anti-HCTLA-4 antibodies | |
| US10494436B2 (en) | Anti-PD-1 antibodies | |
| EP3503920B1 (en) | Anti-ctla4 antibodies | |
| WO2023072177A1 (en) | Anti-cd47 antibodies and methods of use thereof | |
| TWI888925B (zh) | 抗ctla4抗體及其製備及使用方法 | |
| BR122023018935B1 (pt) | Anticorpo, polinucleotídeo, vetor, célula hospedeira bacteriana, método de produção de um anticorpo, composição farmacêutica e uso do anticorpo | |
| HK40006481B (en) | Anti-ctla4 antibodies | |
| HK40006481A (en) | Anti-ctla4 antibodies |